Comparison of outcomes of hysteroscopic myomectomy of type 2 submucous fibroids greater than 4 cm in diameter via pretreatment with HIFU or GnRH-a

Liao, Ping; Jiang, Jing; Zeng, Yu-hua; Chen, Yan; Yong, Min; Qu, Dacheng; Zhou, Hailin

doi:10.1080/02656736.2021.1874546

Cited by 4 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study by Liao et al 22 demonstrated that among the 31 patients with HIFU, the fibroids were downgraded to type 0 in 10 cases and type I in 5 cases. It shows that high intensity focused ultrasound (HIFU); reduces the size of the larger fibroids of type II and type III (close to endometrium) downgrade, so TCRM is safe and feasible.…”

Section: Discussionmentioning

confidence: 99%

“…uterine submucosal fibroids <3 cm in length, the intervention time in the TCRM group was (34.2 ± 9.9) min, which was significantly lower compared to (40.0 ± 8.1) min in the PMWA group. The incidence of perioperative complications (postoperative fever) was 4.2%, 1 in 24 patients in the TCRM group, compared to 6 in 25 (24%) patients with postoperative abdominal pain in the PMWA group.A recent study by Liao et al22 demonstrated that among the 31 patients with HIFU, the fibroids were downgraded to type 0 in 10 cases and type I in 5 cases. It shows that high intensity focused ultrasound (HIFU); reduces the size of the larger fibroids of type II and type III (close to endometrium) downgrade, so TCRM is safe and feasible.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Optimal treatment options for uterine submucosal fibroids: Percutaneous microwave ablation versus transcervical resection of myoma

Jin

Chen

et al. 2023

J of Clinical Ultrasound

View full text Add to dashboard Cite

Objectives To compare the efficacy and safety of percutaneous microwave ablation (PMWA) and transcervical resection of myoma (TCRM) for submucosal fibroids. Methods From January 2019 to January 2021, we conducted a randomized controlled study involving patients with symptomatic uterine submucosal fibroids. Questionnaires were also used to measure the uterine fibroid symptom (UFS) scores and quality of life (QoL) scores before and after treatment at 3, 6, and 12 months. Outcomes, adverse events, hemoglobin recovery, and submucosal fibroid volume of both groups were also compared. Operation time, amount of bleeding, hospital stay time, and occurrence of complications were compared in groups with fibroids of different lengths. Results Follow‐up after surgery showed that UFS scores at 3, 6, and 12 months were significantly lower in each group, while QoL scores increased significantly. For fibroids less than 3 cm, surgical time was 34.2 ± 9.9 min, incidence of perioperative complications was 4.2%, and both decreased significantly, compared to the surgical time of the PMWA group (40.0 ± 8.1 min) and incidence of perioperative complications (24%; p < .05 for both). For uterine submucosal fibroids >5 cm, the operation time in the PMWA group was 92.7 ± 16.0 min, intraoperative bleeding volume was 22.7 ± 6.4 mL, and hospital stay was 2.7 ± 1.1 days, which were significantly less than the procedural time (107 ± 11.9 min), intraoperative bleeding loss (45.9 ± 12.8 mL), and length of hospital stay (5.0 ± 1.1 days) in the TCRM group. The differences were statistically significant (p < .05). Conclusions PMWA and TCRM were both effective treatments for uterine submucosal fibroids. For fibroids shorter than 3 cm in length, especially pedicled submucosal fibroids, TCRM has absolute advantages; however, for uterine submucosal fibroids >5 cm, PMWA avoids perioperative complications, such as uterine perforation, water poisoning syndrome, and the need for repeat surgery, and is considered the preferred mode of treatment. Therefore, personalized treatment should be used for different patients with uterine submucosal fibroids.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Optimal treatment options for uterine submucosal fibroids: Percutaneous microwave ablation versus transcervical resection of myoma

Jin

Chen

et al. 2023

J of Clinical Ultrasound

View full text Add to dashboard Cite

show abstract

Post treatment and 3 month contrast enhanced MRI findings following HIFU of submucosal fibroids: a retrospective study

Tang

Lin

et al. 2023

International Journal of Hyperthermia

View full text Add to dashboard Cite

Evaluation of the timing and safety of hysteroscopic myomectomy of large submucosal fibroids pretreated by high intensity focused ultrasound

Qu,

Zou,

Wang

et al. 2023

International Journal of Hyperthermia

View full text Add to dashboard Cite

Comparison of outcomes of hysteroscopic myomectomy of type 2 submucous fibroids greater than 4 cm in diameter via pretreatment with HIFU or GnRH-a

Abstract: Zhou (2021) Comparison of outcomes of hysteroscopic myomectomy of type 2 submucous fibroids greater than 4 cm in diameter via pretreatment with HIFU or GnRH-a ,

Cited by 4 publications

References 24 publications

Optimal treatment options for uterine submucosal fibroids: Percutaneous microwave ablation versus transcervical resection of myoma

Optimal treatment options for uterine submucosal fibroids: Percutaneous microwave ablation versus transcervical resection of myoma

Post treatment and 3 month contrast enhanced MRI findings following HIFU of submucosal fibroids: a retrospective study

Evaluation of the timing and safety of hysteroscopic myomectomy of large submucosal fibroids pretreated by high intensity focused ultrasound

Contact Info

Product

Resources

About